The influence of interferon-γ and various phagocytic stimuli on the expression of MHC-class II antigens on human monocytes — relation to the generation of reactive oxygen intermediates

Volk, Hans‐Dieter; Grüner, Stefan; Falck, P; Baehr, R. von

doi:10.1016/0165-2478(86)90057-x

Cited by 12 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cytokine chiefly responsible for their proinflammatory effect is IFN-g. IFN-g stimulates phagocytosis [40,41], the oxidative burst [42,43], and intracellular killing of microbes [44][45][46]. IFN-g also upregulates expression of class I [47,48] and class II major histocompatibility complex (MHC) molecules [49,50] on a variety of cells, thereby stimulating antigen presentation to T cells (figure 2). Both IFN-g and LT-a induce other cell types, including nonleukocytes such as endothelial cells [51], keratinocytes [52], and fibroblasts [53,54], to secrete proinflammatory cytokines, such as TNF and chemotactic cytokines called chemokines [55].…”

Section: Th1/th2 Cell Biologymentioning

confidence: 99%

Type 1/Type 2 Immunity in Infectious Diseases

Spellberg

Edwards

2001

Clinical Infectious Diseases

743

548

View full text Add to dashboard Cite

T helper type 1 (Th1) lymphocytes secrete secrete interleukin (IL)-2, interferon-gamma, and lymphotoxin-alpha and stimulate type 1 immunity, which is characterized by intense phagocytic activity. Conversely, Th2 cells secrete IL-4, IL-5, IL-9, IL-10, and IL-13 and stimulate type 2 immunity, which is characterized by high antibody titers. Type 1 and type 2 immunity are not strictly synonymous with cell-mediated and humoral immunity, because Th1 cells also stimulate moderate levels of antibody production, whereas Th2 cells actively suppress phagocytosis. For most infections, save those caused by large eukaryotic pathogens, type 1 immunity is protective, whereas type 2 responses assist with the resolution of cell-mediated inflammation. Severe systemic stress, immunosuppression, or overwhelming microbial inoculation causes the immune system to mount a type 2 response to an infection normally controlled by type 1 immunity. In such cases, administration of antimicrobial chemotherapy and exogenous cytokines restores systemic balance, which allows successful immune responses to clear the infection.

show abstract

Section: Th1/th2 Cell Biologymentioning

confidence: 99%

Type 1/Type 2 Immunity in Infectious Diseases

Spellberg

Edwards

2001

Clinical Infectious Diseases

743

548

View full text Add to dashboard Cite

show abstract

“…MHC class II expression is central to immune regulation in T-cell-mediated autoimmune disease (Steinman et al 1980; Steinman et al 1981; Bottazzo et al 1983; Slavin et al 2001). Zymosan prevented IFN-γ-inducible MHC class II expression on monocytes (Volk et al 1986), suggesting that zymosan might inhibit antigen presentation to pro-inflammatory Th cells (Volk et al 1986). In the Volk et al .…”

Section: Introductionmentioning

confidence: 99%

“…In the Volk et al . study, it was observed that following digestion of phagocytosed zymosan particles, IFN-γ could not restore MHC class II antigen expression on cultured monocytes, suggesting that soluble yeast β-glucan may work in a different way than whole yeast β-glucan particles (WGPs) (Volk et al 1986). Although resident macrophages were effectively activated by WGPs, the binding ability of WGPs and the levels of cytokine secretion in resident macrophages were significantly inhibited by soluble yeast β-glucan, but not by blockade of the zymosan glucan receptor dectin-1.…”

Section: Introductionmentioning

confidence: 99%

Low dose zymosan ameliorates both chronic and relapsing experimental autoimmune encephalomyelitis

Gonnella

Safavi

et al. 2013

Journal of Neuroimmunology

View full text Add to dashboard Cite

Zymosan has previously been reported to have both pro-inflammatory and anti-inflammatory effects. Here we demonstrate that low dose zymosan prevented or reversed chronic and relapsing paralysis in EAE. In suppressing CNS autoimmune inflammation, zymosan not only regulated APC costimulator and MHC class II expression, but also promoted differentiation of regulatory T cells. Following adoptive transfer of zymosan-primed CD4+ T cells, recipient mice were protected from EAE. In contrast, a MAPK inhibitor and a blocker of β-glucan, reversed the effects of zymosan. These results demonstrate that zymosan may be a promising beneficial agent for Multiple Sclerosis (MS).

show abstract

“…Th1 tend to produce proinflammatory cytokines, such as interferon γ (IFNγ), which support cell‐mediated immunity, oxidative burst/microbial killing, and cytotoxic T‐cell response. In addition, IFN gamma up‐regulates HLA‐DR expression (21–22). Th2 cells tend to produce IL‐4 and IL‐10, which support B‐cell function and humoral immunity (22).…”

mentioning

confidence: 99%

Human leukocyte antigen‐DR expression on peripheral blood monocytes and the risk of pneumonia in pediatric lung transplant recipients

Hoffman¹,

Weinberg²,

Azen³

et al. 2004

Transplant Infectious Dis

View full text Add to dashboard Cite

Persistent low monocyte HLA-DR expression was associated with the risk of post-LT pneumonia in these patients. This measurement may be useful for monitoring risk of infection and stratifying patients into higher and lower risk groups. Increased IL-10 levels may be protective for infection in this group of patients. At present it is unknown whether the predictive power of HLA-DR expression is indicative of a global defect in monocytic function or a specific abnormality.

show abstract

The influence of interferon-γ and various phagocytic stimuli on the expression of MHC-class II antigens on human monocytes — relation to the generation of reactive oxygen intermediates

Cited by 12 publications

References 7 publications

Type 1/Type 2 Immunity in Infectious Diseases

Type 1/Type 2 Immunity in Infectious Diseases

Low dose zymosan ameliorates both chronic and relapsing experimental autoimmune encephalomyelitis

Human leukocyte antigen‐DR expression on peripheral blood monocytes and the risk of pneumonia in pediatric lung transplant recipients

Contact Info

Product

Resources

About